Contents
Understanding prostate cancer symptoms and detection can be challenging because early prostate cancer often causes no noticeable symptoms. When urinary or sexual symptoms do occur, they may also be caused by noncancerous conditions such as benign prostatic hyperplasia, or BPH, prostatitis, urinary tract infections, bladder disorders, or other health concerns.
For this reason, prostate cancer cannot be identified from symptoms alone. A PSA Total Test may help identify prostate changes that deserve further evaluation, but an abnormal PSA result does not diagnose cancer. Follow-up may include repeat PSA testing, a physical examination, additional biomarkers, prostate imaging, or a biopsy.
The National Cancer Institute estimates that 333,830 new cases of prostate cancer and 36,320 deaths from the disease will occur in the United States in 2026. Prostate cancer is most frequently diagnosed between ages 65 and 74, although age is only one part of an individual’s risk.
Ulta Lab Tests provides direct access to prostate and urinary laboratory testing, including the PSA Total Test, PSA Free and Total Test, Urinalysis Complete Test, and Urine Culture Test.
Medical disclaimer: Laboratory testing provides health information but does not diagnose prostate cancer or replace professional medical advice. Abnormal results and concerning symptoms should be reviewed with a qualified healthcare provider.
Prostate cancer begins when cells in the prostate grow abnormally. The prostate is a gland located below the bladder and in front of the rectum. It surrounds part of the urethra, the tube that carries urine out of the body, and produces fluid that contributes to semen.
Some prostate cancers grow slowly and may never cause serious health problems. Others grow more quickly and may spread beyond the prostate to nearby tissues, lymph nodes, bones, or other organs.
Because prostate cancers do not all behave in the same way, early detection is not simply about finding every abnormal prostate cell. The goal is to identify cancers that may become clinically significant while reducing unnecessary biopsies, treatment, anxiety, and complications from finding cancers that might never have caused harm.
Early-stage prostate cancer usually causes no symptoms. Symptoms are more likely when a tumor has grown enough to affect urinary function or when cancer has spread outside the prostate.
Even then, the same symptoms can occur with benign prostate enlargement, inflammation, urinary infection, bladder disorders, kidney disease, medication effects, or other medical conditions.
Direct answer: Prostate cancer may be present without symptoms, and symptoms alone cannot determine whether cancer is present. PSA testing and clinician-directed evaluation provide more objective information.
Detecting clinically significant prostate cancer at an earlier stage may provide more options for evaluation, monitoring, and treatment. However, prostate cancer screening is not automatically appropriate for every person at the same age or frequency.
The screening decision may depend on:
Modern prostate cancer detection uses a risk-adapted approach. Rather than relying on one PSA cutoff, healthcare providers may consider repeat PSA measurements, the percentage of free PSA, physical examination findings, prostate size, MRI results, secondary biomarkers, prior biopsy history, and validated risk calculators.
| Symptom or Risk Factor | What It May Suggest | Tests or Evaluation That May Help |
|---|---|---|
| Weak or interrupted urine flow | BPH, prostate inflammation, urinary obstruction, or advanced prostate disease | PSA Total Test, urinalysis, and a clinical prostate examination |
| Difficulty starting urination | Prostate enlargement, obstruction, inflammation, or another urinary condition | PSA Total Test, Urinalysis Complete Test, and urologic evaluation |
| Frequent urination, especially at night | BPH, diabetes, urinary infection, bladder disease, medication effects, or prostate disease | Urinalysis Complete Test, Urine Culture Test when indicated, and PSA Total Test |
| Pain or burning during urination | Urinary infection, prostatitis, bladder irritation, or another urinary condition | Urinalysis Complete Test and Urine Culture Test |
| Blood in urine or semen | Infection, stones, inflammation, prostate disease, bladder disease, or another condition requiring evaluation | Urinalysis Complete Test, PSA testing, and prompt medical evaluation |
| Erectile dysfunction | Vascular, neurologic, hormonal, medication-related, psychological, or advanced prostate disease | Clinical evaluation with laboratory testing selected according to the suspected cause |
| Persistent pain in the back, hips, pelvis, or ribs | Musculoskeletal disease or, less commonly, prostate cancer that has spread to bone | Prompt clinical evaluation and clinician-directed imaging |
| Leg weakness or numbness | Possible spinal or neurologic compression | Urgent medical evaluation |
| Increasing age | Prostate cancer becomes more common with age | Shared decision-making about PSA screening |
| Black ancestry | Associated with a higher incidence of prostate cancer and higher prostate cancer mortality | Earlier risk discussion and individualized screening plan |
| Father or brother with prostate cancer | Possible familial or inherited risk | Earlier PSA screening discussion and genetic counseling in selected families |
| BRCA2 or certain other inherited variants | May increase the risk of developing prostate cancer, including aggressive disease | Genetic counseling and an individualized screening plan |
Early prostate cancer is usually asymptomatic. More advanced disease may cause urinary difficulties, blood in urine or semen, erectile problems, bone pain, or neurologic symptoms. These symptoms are not specific to prostate cancer and require professional evaluation.
Seek prompt or urgent medical care for:
Age is one of the strongest prostate cancer risk factors. The National Cancer Institute reports that prostate cancer is most frequently diagnosed between ages 65 and 74, with a median age at diagnosis of 68.
People may warrant an earlier prostate cancer screening discussion when they have:
Inherited harmful BRCA2 variants, and to a lesser degree BRCA1 variants, are associated with increased prostate cancer risk. Genetic testing should generally be guided by personal and family history and accompanied by appropriate genetic counseling.
Prostate cancer detection usually occurs in stages. A screening result identifies possible risk; it does not confirm that cancer is present.
PSA stands for prostate-specific antigen. It is a protein produced by both normal and abnormal prostate cells.
The PSA Total Test measures the concentration of PSA in the blood, generally reported in nanograms per milliliter, or ng/mL.
A higher PSA level may be associated with prostate cancer, but it may also occur because of:
Certain medications, particularly finasteride and dutasteride, may lower PSA and change how a result should be interpreted.
Direct answer: A PSA test can show that additional evaluation may be appropriate, but no PSA value can prove that a person has or does not have prostate cancer.
During a digital rectal examination, or DRE, a healthcare professional feels the prostate through the rectal wall. The examination may identify a hard area, nodule, asymmetry, tenderness, or prostate enlargement.
A DRE is less effective than PSA testing for finding many early prostate cancers, but it may provide additional information when symptoms, PSA results, or other findings are concerning.
PSA levels may fluctuate. When a PSA result is newly elevated, a healthcare provider may recommend repeating the PSA Total Test before ordering prostate imaging, secondary biomarkers, or a biopsy.
Repeat testing may be particularly useful when:
PSA circulates in the blood in free and protein-bound forms. The PSA Free and Total Test measures total PSA, free PSA, and the relationship between the two.
The percentage of free PSA is calculated by dividing free PSA by total PSA and multiplying by 100. In general, a lower percentage of free PSA may be associated with a higher likelihood of prostate cancer, particularly when the total PSA falls within a borderline range.
Percent-free PSA may help a healthcare provider decide whether continued monitoring, prostate MRI, another biomarker, or biopsy should be considered. It is not a stand-alone cancer test.
Depending on availability and individual circumstances, a urologist may consider additional tests such as:
Validated prostate cancer risk calculators may combine:
These tools may help estimate the likelihood of clinically significant cancer, but they do not replace a biopsy when tissue confirmation is needed.
Multiparametric magnetic resonance imaging, or mpMRI, creates detailed images of the prostate and surrounding tissues.
A prostate MRI may help:
MRI can miss some prostate cancers and cannot independently confirm a cancer diagnosis.
A prostate biopsy removes small tissue samples for examination under a microscope. A biopsy is the procedure used to confirm whether prostate cancer is present and to evaluate the cancer’s grade.
Samples may be obtained through the perineum or rectum, often with ultrasound, MRI, or combined MRI-ultrasound guidance.
A pathology report may include:
Prostate cancer screening recommendations vary slightly among professional organizations, but they consistently emphasize informed, shared decision-making.
The American Urological Association and Society of Urologic Oncology amended their early-detection guidance in 2026. The recommendations support:
The American Cancer Society recommends discussing screening:
The screening discussion should include potential benefits as well as the possibility of false-positive results, overdiagnosis, prostate biopsy complications, and treatment-related side effects.
Laboratory testing may help patients and healthcare providers:
Laboratory testing cannot:
PSA velocity, which refers to the rate at which PSA changes over time, should not be used as the sole reason to order an additional biomarker, prostate MRI, or biopsy. Results should be considered with age, repeat PSA values, family history, medications, prostate size, physical examination findings, and other clinical information.
| Laboratory Test | What It Measures | Why It May Be Relevant | What Results May Generally Suggest | Important Limitations |
|---|---|---|---|---|
| PSA Total Test | Total prostate-specific antigen in the blood | Primary blood test used for prostate cancer screening, risk assessment, and evaluation of prostate-related concerns | A higher result may be associated with prostate cancer, BPH, prostatitis, infection, urinary retention, age, or recent prostate stimulation | Cannot diagnose or exclude cancer; no universal PSA cutoff applies to everyone |
| PSA Free and Total Test | Free PSA, total PSA, and the percentage of PSA circulating in the free form | May help clarify risk when total PSA is elevated or within a borderline range | A lower percent-free PSA may be associated with a greater likelihood of prostate cancer | Interpretation depends on total PSA and clinical context; does not replace MRI or biopsy |
| Repeat PSA Total Test | A second total PSA measurement | Helps determine whether an unexpected elevation persists or may have been temporary | A return toward baseline may suggest a temporary influence; persistent elevation may require further evaluation | Timing should account for infection, ejaculation, procedures, medications, and other factors |
| Urinalysis Complete Test | Physical, chemical, and microscopic characteristics of urine | May help evaluate urinary frequency, burning, discomfort, blood, or other urinary symptoms | Abnormal findings may suggest infection, inflammation, kidney disease, stones, diabetes, or another urinary condition | Does not screen for, diagnose, or exclude prostate cancer |
| Urine Culture Test | Growth and identification of bacteria or yeast in urine | May be appropriate when urinary symptoms or urinalysis findings suggest infection | Significant microbial growth may support the presence of a urinary tract infection | Does not evaluate or exclude prostate cancer |
| Secondary prostate biomarkers | Various PSA forms, kallikreins, RNA markers, or other molecular biomarkers | May help a urologist estimate whether MRI or biopsy should be considered | Results may estimate the probability of clinically significant prostate cancer | Availability and interpretation vary; these tests do not independently diagnose cancer |
| Hereditary cancer genetic testing | Inherited variants such as BRCA2, BRCA1, ATM, CHEK2, HOXB13, and mismatch-repair genes | May be considered when personal or family history suggests inherited cancer risk | A pathogenic variant may indicate increased inherited risk and may affect screening recommendations | Requires informed consent, careful test selection, and professional genetic interpretation |
A baseline or periodic PSA measurement may be considered after discussing the potential benefits and limitations of prostate cancer screening with a healthcare provider. Not every person needs screening at the same age or frequency.
An unexpected PSA elevation may be repeated after potential temporary influences have resolved. Testing too soon after infection, urinary retention, ejaculation, cycling, catheterization, cystoscopy, or prostate biopsy may complicate interpretation.
This test may be considered when total PSA is elevated or within a borderline range and a healthcare provider needs additional information before recommending MRI or biopsy.
This test may help identify blood, white blood cells, glucose, protein, crystals, bacteria indicators, or other abnormalities that could help explain urinary symptoms.
This test may be appropriate when burning, urgency, fever, pelvic discomfort, or urinalysis findings suggest a urinary tract infection.
Urinalysis and urine culture may help evaluate alternative explanations for urinary symptoms. They are not prostate cancer screening tests.
Depending on PSA results, symptoms, physical examination findings, and individual risk, a healthcare provider may recommend:
PSA is a continuous risk marker. The likelihood of prostate cancer generally rises as PSA increases, but cancer may sometimes be found at a relatively low PSA, while a high PSA may have a noncancerous explanation.
Many clinicians have historically used values such as 4.0 ng/mL to prompt further evaluation. Others consider lower values, age, previous results, inherited risk, prostate size, symptoms, and overall health.
A laboratory reference range should not be treated as a diagnostic boundary.
Tell the healthcare provider interpreting the result about prescription medications, over-the-counter products, supplements, urinary symptoms, infections, and recent prostate procedures.
A single PSA value is only one data point. Comparing results over time may provide useful context, especially when testing is performed with the same laboratory method.
However, the rate of PSA change should not independently determine whether a person needs MRI or biopsy.
An elevated result means more information may be needed. It does not mean prostate cancer is present.
Follow-up may involve:
Some prostate cancers produce relatively little PSA. Persistent symptoms, an abnormal physical examination, strong inherited risk, or another concerning finding may require evaluation even when PSA falls within the laboratory reference range.
Always follow the preparation instructions provided for the specific test. General considerations include:
Do not stop a prescription medication or change treatment solely to prepare for a PSA test. Ask the prescribing healthcare provider how the medication should be considered when interpreting the result.
Ulta Lab Tests provides convenient access to many prostate and urinary laboratory tests through direct online ordering where available.
Patients can:
Relevant testing options include:
Patients can also explore the Prostate Cancer Testing and Prostate Blood Tests categories.
Direct-access testing can make laboratory information easier to obtain, but an abnormal PSA result or concerning symptom should be reviewed with a qualified healthcare provider. Ulta Lab Tests does not diagnose prostate cancer, determine whether a biopsy is needed, or replace specialist care.
Early prostate cancer usually causes no symptoms. When symptoms occur, they may include weak urine flow, difficulty starting urination, frequent nighttime urination, blood in urine or semen, erectile difficulties, or persistent pelvic or bone pain. These symptoms are often caused by noncancerous conditions, so professional evaluation is necessary.
Yes. A PSA Total Test may identify a prostate abnormality before symptoms develop. However, PSA can also rise because of BPH, inflammation, infection, age, or recent prostate-related activity. A PSA result estimates risk and may lead to further evaluation; it does not diagnose prostate cancer.
The primary blood test is the PSA Total Test. It measures prostate-specific antigen produced by normal and abnormal prostate cells. The result should be interpreted with age, medications, family history, symptoms, previous PSA results, and clinical examination findings.
No PSA level proves that prostate cancer is present. Cancer becomes more likely as PSA rises, but some people with high PSA do not have cancer, while some people with lower PSA do. A healthcare provider may recommend repeat testing, percent-free PSA, MRI, a risk calculator, or biopsy rather than relying on one cutoff.
BPH, prostatitis, urinary infection, urinary retention, ejaculation, cycling, increasing age, catheterization, cystoscopy, prostate biopsy, and other prostate procedures may raise PSA. Finasteride and dutasteride may lower PSA. These influences are important when choosing the timing of testing and interpreting a result.
A newly elevated PSA is often repeated, particularly when the increase is modest or a temporary influence may be present. The appropriate timing depends on the PSA value, urinary symptoms, infection status, recent procedures, medications, and overall risk. A markedly elevated PSA or concerning examination may require more immediate specialist evaluation.
Percent-free PSA compares free PSA with total PSA. A lower percentage may be associated with a greater chance of prostate cancer, particularly when total PSA is in a borderline range. The PSA Free and Total Test may help guide decisions about continued monitoring, MRI, or biopsy, but it cannot confirm or exclude cancer.
No. Depending on the PSA level and overall risk, the next step may be repeating PSA, measuring free and total PSA, using another biomarker, completing a digital rectal examination, or obtaining prostate MRI. Biopsy may be recommended when the combined findings indicate a meaningful possibility of clinically significant cancer.
No. The Urinalysis Complete Test does not screen for or diagnose prostate cancer. It may reveal blood, white blood cells, bacteria indicators, glucose, protein, or other findings that can help identify infection, kidney disease, stones, diabetes, or another explanation for urinary symptoms.
The Urine Culture Test may be helpful when urinary burning, urgency, frequency, fever, pelvic discomfort, or urinalysis findings suggest a bacterial or yeast infection. A urine culture does not evaluate or exclude prostate cancer.
Ulta Lab Tests allows patients to order the PSA Total Test and PSA Free and Total Test directly online where available. Patients should understand the benefits and limitations of screening and review abnormal or changing results with a healthcare provider.
The appropriate interval depends on age, baseline PSA, family history, ancestry, inherited risk, overall health, and personal preferences. Current guidance supports individualized testing rather than automatic annual screening for everyone. Some average-risk adults may be screened every two to four years, while higher-risk individuals may need an earlier or more personalized plan.
No. A normal or lower PSA may reduce concern in many situations, but it does not completely rule out prostate cancer. Persistent symptoms, an abnormal prostate examination, strong family history, or a known inherited variant may justify additional evaluation despite a result within the laboratory reference range.
Understanding prostate cancer symptoms and detection begins with recognizing that early prostate cancer often causes no symptoms and that common urinary problems do not automatically indicate cancer.
The PSA Total Test may provide valuable information about prostate health, but it is a risk-assessment tool rather than a diagnostic test. The safest approach is to interpret PSA alongside age, family history, ancestry, medications, symptoms, repeat results, physical examination findings, imaging, and personal preferences.
Ulta Lab Tests provides convenient access to the PSA Total Test, PSA Free and Total Test, Urinalysis Complete Test, and Urine Culture Test.
Explore Prostate Cancer Testing from Ulta Lab Tests
Review abnormal PSA results, changing PSA trends, and concerning symptoms with a qualified healthcare provider.
Prostate cancer is abnormal cell growth that begins in the prostate gland. Early prostate cancer often causes no symptoms, so detection may involve PSA blood testing followed by repeat testing, physical examination, secondary biomarkers, prostate MRI, or biopsy when appropriate.
Related laboratory tests: PSA Total Test, PSA Free and Total Test, Urinalysis Complete Test, and Urine Culture Test.
Ulta Lab Tests helps patients access many prostate and urinary laboratory tests directly online with transparent pricing and secure results.
Laboratory testing is informational and should be reviewed with a qualified healthcare provider.
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
